Renalytix PLC Renalytix to Present at Growth Stock Conference

TIDMRENX

Renalytix PLC

08 June 2022

Renalytix to Present at 42(nd) Annual William Blair Growth Stock Conference

NEW YORK and SALT LAKE CITY, June 8, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42(nd) Annual William Blair Growth Stock Conference on Thursday, June 9 at 2:00 p.m. CT. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at investors.renalytix.com.

For further information, please contact:

 
Renalytix plc                                                        www.renalytix.com 
James McCullough, CEO                                                  Via Walbrook PR 
 
Stifel (Nominated Adviser, Joint Broker                             Tel: 020 7710 7600 
 ) 
Alex Price / Nicholas Moore 
 
Investec Bank plc (Joint Broker)                                    Tel: 020 7597 4000 
Gary Clarence / Daniel Adams 
 
Walbrook PR Limited                     Tel: 020 7933 8780 or renalytix@walbrookpr.com 
Paul McManus / Lianne Applegarth /                  Mob: 07980 541 893 / 07584 391 303 
 Alice Woodings                                                        / 07407 804 654 
 
CapComm Partners                          Tel: 415-389-6400 or investors@renalytix.com 
Peter DeNardo

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis(TM) for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory-developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D with early CKD stages 1-3. We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFRMMTMTIMTPT

(END) Dow Jones Newswires

June 08, 2022 02:01 ET (06:01 GMT)

Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From Mar 2024 to Apr 2024